Vanguards of Health Care by Bloomberg Intelligence
Dexcom's Stelo Expands CGMs to Non-Insulin Type 2
04 Apr 2024
Dexcom is expanding its portfolio of continuous glucose monitors (CGMs) with the launch of Stelo, balancing the needs of patients and payors to maximize the use of the technology, CEO Kevin Sayer explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sayer sits down with BI analyst Matt Henriksson for an in-depth interview about how G7, Dexcom’s flagship CGM, is capturing share in every market it’s in, how the launch of Stelo opens up CGM access to nearly 25 million Type 2 diabetes patients in the US and how any patient can order the new CGM without a prescription.See omnystudio.com/listener for privacy information.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Vanguards of Health Care by Bloomberg Intelligence
Transcribed and ready to explore now
Aegis Ventures’ Blueprint for Building AI-Native Companies
04 Dec 2025
Vanguards of Health Care by Bloomberg Intelligence
Beta Bionics Does the Work to Reduce Insulin Pump Burden
20 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Fosun Pharma’s Drive Beyond China
17 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
ARS Pharma’s Clinical Differentiation
13 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Biolinq Introduces New Silicon Tech Opens Next Chapter of Glucose and Analyte Detection
06 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates
27 Oct 2025
Vanguards of Health Care by Bloomberg Intelligence